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OBJECTIVES We performed a multicenter, double-blind placebo-controlled trial to examine the efficacy
and safety of enoxaparin in patients at high risk for stent thrombosis (ST).
BACKGROUND The optimal antithrombotic regimen for such patients is unknown.
METHODS We randomized 1,102 patients with clinical, angiographic or ultrasonographic features
associated with an increased risk of ST to receive either twice-daily injections of weight-
adjusted enoxaparin or placebo for 14 days after stenting. All patients received aspirin and
ticlopidine. The primary end point was a 30-day composite end point of death, myocardial
infarction (MI) or urgent revascularization.
RESULTS The target enrollment for the study was 2,000 patients. However, the trial was terminated
prematurely at 1,102 patients after interim analysis revealed an unexpectedly low event rate.
The primary outcome occurred in 1.8% enoxaparin-treated patients versus 2.7% treated with
placebo (odds ratio [OR] 0.66; 95% confidence interval [CI] 0.29 to 1.5, p 0.30); for death
or MI the rates were 0.9% vs. 2.2%, respectively (OR 0.41, 95% CI 0.14 to 1.2, p  0.13);
and for MI, 0.4% vs. 1.6%, respectively (OR 0.22, 95% CI 0.05 to 0.99, p  0.04). The
groups had comparable rates of major bleeding (3.3% for enoxaparin, 1.6% for placebo, p 
0.08), but minor nuisance bleeding was increased with enoxaparin (25% vs. 5.1%, p 0.001).
CONCLUSIONS The clinical outcomes of patients at increased risk of ST are more favorable than previously
reported, rendering routine oral antiplatelet therapy adequate for most. However, given its
relative safety and potential to reduce the risk of subsequent infarction, a 14-day course of
enoxaparin may be considered for carefully selected patients. (J Am Coll Cardiol 2001;38:
1608–13i) © 2001 by the American College of Cardiology
Platelet-fibrin thrombus is central to the pathophysiology of
stent thrombosis (ST) (1–8). After successful elective cor-
onary stenting, dual oral antiplatelet therapy (aspirin and a
thienopyridine) reduces the risk of ST (1,4,8). However,
when stents are urgently implanted for abrupt vessel closure,
or when stent deployment is suboptimal, the risks of
thrombotic complications such as ST increase at least
twofold, to between 3% and 10% (1,2). Although intrave-
nous platelet glycoprotein IIb/IIIa inhibitors reduce
periprocedural thrombotic events after both elective and
unplanned coronary stenting (9,10), the optimal outpatient
antithrombotic regimen for patients at increased risk for ST
following hospital discharge has not been established.
Low-molecular-weight heparins (LMWHs) have supe-
rior bioavailability, enhanced anti-Xa effects, longer plasma
half-lives, lower rates of thrombocytopenia, greater resis-
tance to inactivation by platelets and potentially greater
antiplatelet effects than unfractionated heparin (UFH) (11–
15). The predictable dose-response of LMWHs obviates
laboratory monitoring, facilitating outpatient administra-
tion. The LMWH enoxaparin sodium has been shown to be
clinically superior to UFH for treatment of acute coronary
syndromes (ACS) (16–18). In a pilot study, a 14-day course
of enoxaparin combined with ticlopidine and aspirin re-
duced thrombotic and bleeding risks after coronary stenting
compared with the Food and Drug Administration (FDA)-
approved post-stent regimen of warfarin, UFH, dextran,
dipyridamole and aspirin (19). We performed this study to
determine whether the addition of a 14-day course of
enoxaparin to oral antiplatelet therapy (aspirin and ticlopi-
dine) would safely reduce postprocedural major thrombotic
events in patients at increased risk of ST.
METHODS
Study population. Each site’s ethics committee approved
the protocol. Patient enrollment occurred between Decem-
ber 1996 and August 1998 in 47 centers across the Neth-
erlands, France, the U.S. and Canada. The study population
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consisted of patients with coronary disease who had received
any FDA-approved stent and were considered to be at
increased risk of ST because of unplanned urgent stenting,
a high likelihood of intracoronary thrombus or suboptimal
stent results (1,2).
Patients were eligible if they had any of the following:
acute MI 48 h before stenting, abrupt closure with
Thrombolysis In Myocardial Infarction (TIMI) grade 0 or 1
flow (20), threatened abrupt closure (TIMI grade 2 flow or
angina with significant residual dissection in a target vessel
3.0 mm) before stenting, ejection fraction 35% by
ventriculography, total occlusion of target vessel 7 days
before stenting, stenting of a degenerated saphenous vein
graft 4 mm in diameter with diffuse distal vessel disease,
placement of a 2.5-mm diameter stent in a vessel2.5 mm,
placement of1 stents in a true bifurcation lesion, or any of
the following by angiography or ultrasound: intracoronary
thrombus (discrete intraluminal filling defect occupying
50% of the target-vessel diameter outlined by intravenous
contrast in 2 orthogonal views), diffuse distal disease
(40% stenosis 10 mm beyond the distal stent margin),
persistent filling defect within the stent, persistent dissec-
tion at the stent margin, or suboptimal stent deployment
based on residual angiographic stenosis 20% or incom-
plete stent apposition by ultrasound (failure to achieve a
stent cross-sectional area 80% of the smallest proximal or
distal reference segment).
Patients were excluded for contraindication to anticoag-
ulation; uncontrolled hypertension (blood pressure
180/110 mm Hg despite treatment); hemoglobin 9
mg/dl; platelet count 100,000/mm3; glycoprotein IIb/IIIa
inhibitor or dipyridamole therapy within 72 h; thrombol-
ysis 6 h; planned coronary artery bypass grafting (CABG)
or percutaneous coronary intervention (PCI) within 30 days
of index stenting; indications for anticoagulation (such as
atrial fibrillation); groin hematoma at sheath site 5 cm
after stenting; allergy or intolerance to aspirin, ticlopidine,
heparin or any LMWH; prior heparin-associated thrombo-
cytopenia; pork allergy; unwillingness or inability to give or
receive subcutaneous injections; or serious noncardiac illness.
Study protocol. Written informed consent was obtained
before or immediately after stenting. Once vascular access
was achieved, UFH was given intravenously; the dose was at
the discretion of the interventional cardiologist. All patients
were treated with open-label, oral aspirin and ticlopidine.
Aspirin (325 mg) was given daily, starting on or before the
day of stenting and continuing for 6 months. Ticlopidine
(250 mg) was given twice daily for 14 days, beginning
72 h before stenting. “Loading” doses of aspirin (650 mg)
and ticlopidine (500 mg) were recommended for patients
not already taking either drug. Stents were implanted in the
standard manner according to local practice. To ensure
compliance with angiographic and intravascular ultrasound-
specified inclusion criteria, the first three angiograms (and
randomly selected procedural angiograms thereafter) and all
intravascular ultrasound tapes were forwarded to a central
core angiographic laboratory (George Washington Univer-
sity Medical Center, Washington, DC) for review. Vascular
access sheaths were removed 4 h after procedural UFH,
and compression applied for 20 min. FDA-approved
vascular closure devices were permitted. An activated clot-
ting time 200 s was required before study drug initiation.
At vascular sheath removal, patients were randomized to
receive twice daily (every 12 h) subcutaneous injections of
either enoxaparin (Lovenox, Aventis Pharma, ) (40 mg in
0.4 ml for patients 65 kg, 60 mg in 0.6 ml for patients
65 kg) or matching placebo (0.4 ml for patients 65 kg,
0.6 ml for patients 65 kg) for 14 days. The first injection
was given 2 h after sheath removal and 4 to 10 h after the
last dose of UFH.
Study committees. A Clinical Events Committee (CEC),
whose members were blinded to treatment allocation, inde-
pendently adjudicated all efficacy and safety end points. A
Data and Safety Monitoring Board (DSMB) reviewed the
trial’s progress in terms of safety, efficacy and compliance.
Neither DSMB nor CEC members participated in the trial
or were affiliated in any way with the study sponsor. The
DSMB made recommendations to a Steering Committee
(SC), whose responsibility was to oversee administrative and
scientific progress, and to amend or terminate the study.
Evaluation of efficacy and safety end points. The primary
end point was a composite of all-cause mortality, nonfatal
MI (or reinfarction, for patients with MI at enrollment) or
urgent revascularization at 30 days. Urgent revascularization
was defined as an urgent need for repeat PCI or CABG.
Nonfatal MI required either an increase in creatine kinase
(CK) or CK-MB (CK-MB taking precedence over CK
when available) to 3 times the upper limit of normal
before discharge, with levels 50% above the preceding
trough when applicable, or new Q waves 0.04 s in 2
contiguous electrocardiographic leads. Myocardial enzymes
(CK or CK-MB) were assessed at 8 and 16 h after the
procedure and every 8 h thereafter until a return to normal,
or hospital discharge. A 12-lead electrocardiogram was
obtained within 2 h after the stent procedure and then daily
until discharge. All myocardial enzyme elevations were
Abbreviations and Acronyms
ACS  acute coronary syndromes
CABG  coronary artery bypass surgery
CEC  Clinical Events Committee
CK  creatine kinase
DSMB  Data and Safety Monitoring Board
FDA  Food and Drug Administration
LMWH  low-molecular-weight heparin
MI  myocardial infarction
PCI  percutaneous coronary intervention
SC  Steering Committee
ST  stent thrombosis
TIMI  Thrombolysis In Myocardial Infarction
UFH  unfractionated heparin
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reviewed by two CEC physicians, who made the final
determination of MI after complete review of biomarker
data, clinical information from the case report form and
additional data from the medical record. Only MIs that
were deemed to have occurred after study-drug initiation
(post-PCI) were counted in the primary efficacy analysis.
Secondary end points included the incidence of the com-
posite end point at 14 days, and of death or MI at 14 and 30
days.
Safety end points included all adverse events, major and
minor bleeding and thrombocytopenia (platelet count
100,000/mm3). Major bleeding included retroperitoneal,
intraocular or intracranial hemorrhage (by magnetic reso-
nance imaging or computerized tomography), or other
clinically overt bleeding associated with death, transfusion
of 1 U of packed red cells or whole blood, a 3-g/dl
decrease in hemoglobin, hemodynamic compromise or need
for surgical intervention. Clinically significant bleeding not
fulfilling the criteria for major bleeding was considered
minor.
Sample-size determination and interim analyses. Based
on published reports (1,2,19), the expected incidence of the
primary end point with placebo was 6.5%. Assuming a 5%
Type I error rate, 1,000 patients per group were required to
have 90% power to detect a 50% relative risk reduction
with enoxaparin. To reassess sample size, a blinded evalu-
ation of the overall primary end point was planned after
enrollment of 500 patients, and a blinded efficacy analysis
after 1,000 patients. Early termination rules for over-
whelming efficacy were established, using Peto’s stopping
rules to maintain an overall p  0.05 at trial completion
(21).
Statistical analysis. Continuous variables were described as
means  SE and compared between groups by one-way
analysis of variance with treatment effect. Categorical vari-
ables were described as percentages and compared with
chi-square statistics, or Fisher exact test for rare events. The
primary and secondary efficacy analyses were performed on
the treated population. All tests were two-sided with a 5%
level of significance (  0.05).
Interim analysis. Interim analysis after 500 patients re-
vealed a lower than expected incidence of the primary end
point (3.5%). Therefore, the SC and DSMB agreed to
include a futility rule to allow premature study termination
if efficacy expectations were unlikely to be met. The DSMB
met on August 7, 1998, and reviewed the blinded data of
825 patients who had completed 30-day event adjudication.
The overall event rate remained only 2.6%. Although no
important safety issues surfaced, futility analysis suggested
that, given the low event rate, the planned sample size of
2,000 would provide insufficient power to address the
primary hypothesis. With the Gould method (22), a sample
size of 3,590 patients would have been required to
Table 1. Baseline Characteristics
Characteristics
Placebo
(n  549)
Enoxaparin
(n  553)
Age (yrs) 61  0.5 59  0.5
Male gender 73% 78%
Race
Caucasian 91% 90%
Black 8% 8%
Other 1% 1%
Hypertension 58% 57%
Hyperlipidemia 53% 54%
Diabetes 28% 24%
Current smoking 32% 33%
Prior infarction 32% 30%
Prior congestive heart failure 9% 8%
Renal disease 3% 3%
Prior bypass surgery 18% 19%
Prior angioplasty 27% 27%
Ejection fraction (%) 51  0.7 51  0.7
Clinical presentation*
Myocardial infarction 43% 47%
Unstable angina 50% 50%
Stable angina 17% 15%
p  0.05 for all comparisons, placebo vs. enoxaparin. *Not mutually exclusive.
Table 2. Procedural and Angiographic Characteristics
Characteristics
Placebo
(n  549)
Enoxaparin
(n  553)
Risk factors for stent thrombosis*
Infarction 48 h 27% 31%
Distal disease beyond stent 24% 21%
Intracoronary thrombus 17% 17%
Total vessel occlusion 14% 13%
Ejection fraction 35% 10% 11%
Persistent dissection at margin 8% 10%
Abrupt closure 7% 5%
Threatened closure 8% 8%
Other 20% 19%
Patients with 1/2/3/4 risk factors 67/25/7/1 66/27/6/1
Stent design*
Palmaz-Schatz 44% 47%
ACS Multi-Link 19% 19%
Gianturco-Roubin II 14% 12%
Gianturco-Roubin I 5% 5%
Medtronic Wiktor 2% 3%
Other 23% 21%
Patients with 1/2/3 stents deployed 65/26/9 65/25/10
Stent diameter (mm) 3.23 0.02 3.22 0.02
Stent length (mm) 18.4 0.3 18.1 0.2
Additional interventions
Rotational atherectomy 4% 3%
Laser 0% 0.2%
Other 2% 2%
Maximum activated clotting time (s) 319 3.9 318 3.8
Angiographic characteristics
Preprocedural TIMI flow grade 0/1/2/3 20/8/17/54 18/8/20/53
Preprocedural stenosis (%) 92 0.4 92 0.3
Postprocedural TIMI flow grade 0/1/2/3 0/0/3/97 0.2/0.2/1.3/98
Postprocedural stenosis (%) 3.7 0.3 3.7 0.3
p  0.05 for all comparisons, placebo vs. enoxaparin. *Not mutually exclusive.
ACS  acute coronary syndromes; TIMI  Thrombolysis In Myocardial
Infarction.
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maintain adequate statistical power (1- 0.80). In view of
this and other challenges facing enrollment (including the
increasingly widespread use of glycoprotein IIb/IIIa inhib-
itors in high-risk stenting), the SC and sponsor later agreed
to terminate the trial; 1,102 patients (553 enoxaparin, 549
placebo) had been enrolled at that point. The following
represent the final CEC-adjudicated results on these pa-
tients.
RESULTS
Clinical and procedural characteristics. The groups
shared similar baseline characteristics (Table 1). Most pa-
tients had only one or two risk factors for ST, the most
common being recent MI, diffuse distal disease or intra-
coronary thrombus (Table 2). Most stents were of Palmaz-
Schatz, ACS Multi-Link or Gianturco-Roubin (Cook)
design. About one third received 1 stent. Mean stent
diameter and length were similar between groups. Adjunc-
tive interventions, such as rotational atherectomy, laser
ablation or other techniques, were used infrequently. TIMI
flow grades and lesion severity were comparable between
groups before and after stenting.
The median intravascular sheath size was 8.0 Fr. The
median time from sheath removal to first dose of study drug
was similar between the enoxaparin and placebo groups (3.3
vs. 3.5 h, respectively, p ns), as was the median time from
the last dose of procedural UFH to first dose of study drug
(8.0 vs. 8.3 h, respectively, p  ns).
Clinical outcomes. The overall incidence of the CEC-
adjudicated primary end point in the final cohort of 1,102
patients was low (2.3%). Fewer enoxaparin-treated patients
experienced the primary end point compared with placebo
(1.8% vs. 2.7%, respectively, Fig. 1); however, this difference
was not statistically significant. Although statistical com-
parisons were not performed between subgroups, risk ap-
peared to be influenced by the type and number of risk
factors, and perhaps also by stent design (Table 3). Enox-
aparin was associated with significantly fewer MIs at both
14 and 30 days (78% relative risk reduction at 30 days), and
a 59% reduction in death or MI that approached statistical
significance at 30 days (Table 4, Fig. 1). Urgent revascular-
ization was infrequent in both groups (Table 4).
Serious and nonserious adverse events also occurred
infrequently in both groups (Table 5). Bleeding was more
common with enoxaparin, but the vast majority was minor
(oozing or ecchymosis at vascular access or subcutaneous
injection sites). Major bleeding was not significantly in-
creased with enoxaparin. Thrombocytopenia and gastroin-
testinal or genitourinary bleeding were rare. There was one
Figure 1. Odds ratios and 95% confidence intervals for the risk of primary and secondary 30-day clinical events with enoxaparin versus placebo. UR 
urgent revasculariztaion.
Table 3. Primary End Point by Risk Factors and Stent Design
Variable
Primary End
Point*
Risk factors†
Infarction 48 h 8/318 (2.5%)
Distal disease beyond stent 8/247 (3.2%)
Intracoronary thrombus 3/186 (1.6%)
Total occlusion 3/149 (2.0%)
Ejection fraction 35% 7/119 (5.9%)
Persistent dissection at margin 3/98 (3.1%)
Threatened closure 5/86 (5.8%)
Abrupt closure 2/65 (3.1%)
Degenerated vein graft 4 mm 1/52 (1.9%)
Target vessel 2.5 mm 1/43 (2.3%)
Bifurcation lesion 1/43 (2.3%)
Persistent filling defect 0/39 (0.0%)
Residual stenosis 20% 0/31 (0.0%)
Other 0/5 (0.0%)
No. of risk factors
1 9/730 (1.2%)
2 16/372 (4.3%)
Stent design
Palmaz-Schatz 14/503 (2.8%)
ACS Multi-Link 0/211 (0.0%)
Gianturco-Roubin II 5/142 (3.5%)
Gianturco-Roubin I 4/52 (7.7%)
Medtronic Wiktor 0/27 (0.0%)
Other 4/249 (1.6%)
*Death, nonfatal myocardial infarction, or urgent revascularization. †Not mutually
exclusive.
ACS  acute coronary syndrome.
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intracranial hemorrhage in the enoxaparin group. Although
most patients tolerated the study drugs well, enoxaparin was
more often discontinued early (24% vs. 13%, p  0.001).
DISCUSSION
ATLAST is the largest study to prospectively evaluate the
efficacy and safety of LMWH for the prevention of ST in
high-risk patients. The most pertinent finding was the low
rate of adverse cardiac events (2.3%), substantially lower
than has been reported in such patients. A 14-day course of
enoxaparin, begun 4 to 10 h after procedural heparin, did
not significantly reduce this low overall event rate, but was
generally well tolerated, safe and associated with a reduced
risk of MI.
Oral antiplatelet therapy effectively reduces ST to 1.6%
in planned, successful stent procedures (4,8). However,
clinical and angiographic characteristics that indicate
thrombus, residual dissection, or suboptimal stent deploy-
ment (such as those forming the inclusion criteria for
ATLAST), increase the risk of thrombotic events, particu-
larly ST, to between 3% and 10% (1–8,19). Intravenous
glycoprotein IIb/IIIa inhibitors improve outcome in both
high-risk and elective PCI, primarily through a reduction in
periprocedural MI (10,23,24). However, these agents have
not been shown to convincingly reduce the risk of ST, and
prolonged IIb/IIIa blockade by oral agents only increases
thrombotic events (25–27). Therefore, the optimal postdis-
charge antithrombotic regimen for patients at increased risk
of ST has remained unclear.
Enoxaparin’s clinical superiority over UFH has been
shown in patients with acute coronary syndromes (16–18).
Extended LMWH therapy (three months) also reduces the
short-term risk of thrombotic events, although benefits are
not sustained at six months (28). Before ATLAST, the
benefit of adding a LMWH to oral antiplatelet therapy in
patients at risk of ST had undergone limited investigation.
Registry data suggest that the combination of ticlopidine,
aspirin and one month of LMWH effectively limits ST to
2% in patients undergoing elective or bailout stenting
(29). The only prospective randomized assessment of LM-
WH’s efficacy after coronary stenting was a small trial
(ENTICES, n 122), which compared the combination of
aspirin, ticlopidine and enoxaparin with the original FDA-
recommended post-stent regimen (UFH, warfarin, aspirin,
dipyridamole and dextran) (19). The enoxaparin, ticlopidine
and aspirin combination significantly reduced stent throm-
bosis (0% vs. 7%), major ischemic events (5% vs. 21%) and
major bleeding or vascular complications (5% vs. 16%). The
ATLAST trial provides a more contemporary assessment of
the incremental benefits of adding LMWH to an oral
antiplatelet regimen for ST prophylaxis.
The most striking observation in ATLAST was the low
30-day event rate (2.3%) in a presumably high-risk cohort.
Although the relatively small number of events precluded
multivariable regression techniques to define independent
outcome predictors, some interesting trends suggest that the
type and number of risk factors, and stent design, may affect
risk. Despite this, even patients with 2 risk factors had a
relatively low event rate (4.3%). By comparison, placebo-
treated patients in prior studies of intravenous glycoprotein
IIb/IIIa inhibitors have had 30-day composite event rates of
10% to 15% (9,23,30–32). The higher event rates recorded
in these studies may be explained in part by the timing of
drug administration and end point evaluation. In the IIb/
IIIa inhibitor trials, study drug was initiated before vessel
injury, and most of the therapeutic benefit reflected preven-
tion of periprocedural MI. In ATLAST, because the study
drug was initiated after PCI, periprocedural CK-MB eleva-
tions were not counted; only MIs believed to occur after
administration of study drug (i.e., those predominantly
related to ST) were included. Furthermore, patient selection
may have also influenced event rates. With the FDA
approving abciximab in 1997, some ATLAST investigators
felt compelled to use abciximab in the highest risk stent
patients, thereby selectively enrolling lower risk patients.
Finally, the traditional clinical and angiographic high-risk
features forming the basis for inclusion into ATLAST
Table 4. Other Secondary Clinical Outcomes
Event
Placebo
(n  549)
Enoxaparin
(n  553)
p
Value
14 days
Death, infarction or urgent
revascularization
2.2% 1.1% 0.15
Death or infarction 1.8% 0.5% 0.049
Death 0.5% 0.4% 0.69
Infarction 1.3% 0.2% 0.038
Urgent revascularization 1.3% 0.7% 0.38
30 days
Death 0.5% 0.5% 1.0
Urgent revascularization 1.8% 1.1% 0.33
Table 5. 30-Day Safety Endpoints
Event
Placebo
(n  549)
Enoxaparin
(n  553)
p
Value
Any adverse event 9.4% 9.2% 0.97
Serious adverse event 7.3% 5.8% 0.31
Any bleeding 6.7% 28% 0.001
Major 1.6% 3.3% 0.08
Minor 5.1% 25% 0.001
Bleeding sites
Skin injection hematoma 5 cm 1.5% 13.9% 0.001
Vascular sheath hematoma 5 cm 1.8% 7.8% 0.001
Other bruising 0.7% 4.2% 0.001
Intracranial 0.0% 0.2% 0.96
Gastrointestinal 2.0% 1.1% 0.33
Genitourinary 0.2% 0.4% 0.96
Epistaxis 0.2% 0.4% 0.96
Other 1.1% 4.4% 0.001
Thrombocytopenia 0.4% 0% 0.48
Premature drug discontinuation 13% 24% 0.001
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(recent MI, diffuse disease beyond the stent, threatened
abrupt vessel closure and so on) may be no longer be
predictive of ST in an era of newer stent designs and
deployment techniques.
Because of the low event rate and premature termination
of the study, the lack of a statistically significant reduction in
the primary end point with enoxaparin could be due to beta
error. The observation that enoxaparin reduced the risk of
subsequent MI does suggest some degree of efficacy, the
clinical significance of which is limited in this setting
because of the overall low risk. Enoxaparin was generally
safe and well tolerated in this study. However, similar to
other studies (16,33), more frequent minor bleeding at
vascular access and drug-injection sites did occur with
enoxaparin, leading to more frequent drug discontinuation
than with placebo. Despite this, enoxaparin rarely caused
major bleeding. This suggests that LMWH can be safely
initiated soon after PCI (within 4 to 10 h), once adequate
vascular access site hemostasis has been achieved.
ATLAST extends our knowledge of the risks and opti-
mal therapy for patients traditionally deemed to be at
increased risk of ST. Clinical outcomes in this setting are
more favorable than previously reported, rendering a post-
stent oral antiplatelet regimen adequate for most patients.
However, given its relative safety and potential to reduce the
subsequent risk of MI due to ST, a 14-day course of
enoxaparin might be justified for carefully selected high-risk
patients. The safety and efficacy of enoxaparin, alone and in
combination with glycoprotein IIb/IIIa inhibitors, to pre-
vent thrombotic complications during PCI is currently
under investigation.
Acknowledgment
We thank Jacqueline Mason, DPhil, for her invaluable
assistance with manuscript preparation.
Reprint requests and correspondence: Dr. James P. Zidar, Duke
University Medical Center, 7405 Hospital North, Box 3290,
Erwin Road, Durham, North Carolina 27710. E-mail:
zidar001@mc.duke.edu.
REFERENCES
1. Mak KH, Belli G, Ellis SG, et al. Subacute stent thrombosis: evolving
issues and current concepts. J Am Coll Cardiol 1996;27:494–503.
2. Cutlip D, Leon M, Ho K, et al. Acute and nine-month clinical
outcomes after “suboptimal” coronary stenting: results from the STent
Anti-thrombotic Regimen Study (STARS) registry. J Am Coll Car-
diol 1999;34:698–706.
3. Lehmann KG, van Suylen RJ, Stibbe J, et al. Composition of human
thrombus assessed by quantitative colorimetric angioscopic analysis.
Circulation 1997;96:3030–41.
4. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three
antithrombotic-drug regimens after coronary artery stenting. N Engl
J Med 1998;339:1665–71.
5. Neumann FJ, Gawaz M, Ott I, et al. Prospective evaluation of
hemostatic predictors of subacute stent thrombosis after coronary
Palmaz-Schatz stenting. J Am Coll Cardiol 1996;27:15–21.
6. Rozenman Y, Lotan C, Mosseri M, et al. Relation of thrombotic
occlusion of coronary stents to the indication for stenting, stent size,
and anticoagulation. Am J Cardiol 1995;75:84–5.
7. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the
Palmaz-Schatz coronary stent. Initial results of a multicenter study.
Circulation 1991;83:148–61.
8. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison
of antiplatelet and anticoagulant therapy after the placement of
coronary artery stents. N Engl J Med 1996;334:1084–9.
9. The EPISTENT Investigators. Randomised placebo-controlled and
balloon-angioplasty-controlled trial to assess safety of coronary stent-
ing with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;
352:87–92.
10. Kereiakes D, Lincoff A, Miller D, et al. Abciximab therapy and
unplanned coronary stent deployment: favorable effects on stent use,
clinical outcomes, and bleeding complications. Circulation 1998;97:
857–64.
11. Antman E, Handin R. Low-molecular-weight heparins: an intriguing
new twist with profound implications. Circulation 1998;98:287–9.
12. Huang J, Shimamura A. Low-molecular-weight heparins. Hematol
Oncol Clin N Am 1998;12:1251–81.
13. Montalescot G, Philippe F, Ankri A, et al. Early increase of von
Willebrand factor predicts adverse outcome in unstable coronary artery
disease: beneficial effects of enoxaparin. Circulation 1999;98:294–9.
14. Weitz J. Low-molecular-weight heparins. N Engl J Med 1997;337:
688–98.
15. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at
therapeutic concentrations and comparisons with a low-molecular-
weight heparin and with a direct thrombin inhibitor. Circulation
1998;97:251–6.
16. Antman E, McCabe C, Gurfinkel E, et al. Enoxaparin prevents death
and cardiac ischemic events in unstable angina/non-Q-wave myocar-
dial infarction: results of the Thrombolysis In Myocardial Infarction
(TIMI) 11B Trial. Circulation 1999;100:1593–601.
17. Antman E, Cohen M, Radley D, et al. Assessment of the treatment
effect of enoxaparin for unstable angina/non-Q-wave myocardial
infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;
100:1602–8.
18. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-
molecular-weight heparin with unfractionated heparin acutely for
unstable coronary artery disease (ESSENCE trial). N Engl J Med
1997;337:447–52.
19. Zidar JP. Low-molecular-weight heparins in coronary stenting (the
ENTICES trial). Am J Cardiol 1998;82:29L–32L.
20. The TIMI Study Group. The Thrombolysis In Myocardial Infarction
(TIMI) Trial. N Engl J Med 1985;312:932–6.
21. Peto R, Pike MC, Armitage P. Design and analysis of randomised
clinical trials requiring prolonged observation of each patient. I:
introduction and design. Br J Cancer 1976;34:585–612.
22. Gould AL. Interim analyses for monitoring clinical trials that do not
materially affect the type I error rate. Stat Med 1992;11:55–66.
23. The EPIC Investigators. Use of a monoclonal antibody directed
against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary
angioplasty. N Engl J Med 1994;330:956–61.
24. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-
controlled trial of platelet glycoprotein IIb/IIIa blockade with primary
angioplasty for acute myocardial infarction. Circulation 1998;98:734–
41.
25. The SYMPHONY Investigators. Comparison of sibrafiban with
aspirin for prevention of cardiovascular events after acute coronary
syndromes: a randomised trial. Lancet 2000;355:337–45.
26. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein
IIb/IIIa inhibition with orbofiban in patients with unstable coronary
syndromes (OPUS-TIMI 16) trial. Circulation 2000;102:149–56.
27. O’Neill WW, Serruys P, Knudtson M, et al. Long-term treatment
with a platelet glycoprotein-receptor antagonist after percutaneous
coronary revascularization. N Engl J Med 2000;342:1316–24.
28. FRISC-II Investigators. Long-term low-molecular-mass heparin in
unstable coronary artery disease: FRISC II prospective randomised
multicentre study [erratum published Lancet 1999;354:1478]. Lancet
1999;354:701–7.
29. Morice MC, Zemour G, Benveniste E, et al. Intracoronary stenting
without coumadin: one-month results of a French multicenter study.
Cathet Cardiovasc Diagn 1995;35:1–7.
30. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor
1613JACC Vol. 38, No. 6, 2001 Batchelor et al.
November 15, 2001:1608–13i Enoxaparin in High-Risk Stenting
blockade and low-dose heparin during percutaneous coronary revas-
cularization. N Engl J Med 1997;336:1689–96.
31. The CAPTURE Investigators. Randomised placebo-controlled trial
of abciximab before and during coronary intervention in refractory
unstable angina: the CAPTURE Study [erratum published Lancet
1997;350:744]. Lancet 1997;349:1429–35.
32. The IMPACT-II Investigators. Randomised placebo-controlled trial
of effect of eptifibatide on complications of percutaneous coronary
intervention: IMPACT-II. Lancet 1997;349:1422–8.
33. The FRISC-II Investigators. Invasive compared with non-invasive
treatment in unstable coronary artery disease: FRISC II prospective
randomised multicentre study. Lancet 1999;354:708–15.
APPENDIX: PARTICIPANTS IN THE ATLAST REGISTRY
Canada: C. Buller, Vancouver General Hospital; G.
Proulx, L’Hopital Laval, Sainte-Foy; P. Seidelin, University
Health Network, Toronto General Hospital; J-F. Tanguay,
Institute de Cardiologie de Montreal.
France: G. Montalescot, Hopital de la Salpetriere, Paris; J.
Machecourt, Hopital A. Michallon, Grenoble; J-L.
Dubois-Rande, Hopital Henri Mondor, Creteil; J. M.
Fauvel, C.H.U. de Rangueil, Toulouse; J-E. Poulard, Cen-
tre Hospitalier General d’Abbeville; A. Vahanian, Hopital
Tenon, Paris.
The Netherlands: F. Kiemeneij, Onze Lieve Vrowe Hos-
pital, Amsterdam.
U.S.: G. R. Aycock, Sacred Heart Hospital, Pensacola; S.
Bailey, UT Health Science Center, San Antonio; J. Beng-
ston, St. Joseph Mercy Hospital, Ann Arbor; P. Berger,
Mayo Clinic, Rochester; J. Burke, Temple University
School of Medicine, Philadelphia; A. S. Brenner, Lakeland
Regional Medical Center; H. Chen, Jacksonville Center for
Clinical Research; G. Christy, St. Vincent Infirmary Med-
ical Center, Little Rock; A. Chu, St. Francis Medical
Center, Peoria; M. Cohen, Allegheny University Medical
Center, Philadelphia; E. Deutsch, New York Hospital/
Cornell Medical Center; M.D. Fausch, University of Wis-
consin Hospital, Madison; R. Federici, Lovelace Medical
Center, Albuquerque; F. Feit, Bellevue Hospital, New
York; E. Fry, St. Vincent Hospital, Indianapolis; M. I.
Furman, U Mass Medical Center, Worcester; J. George,
Shadyside Hospital, Pittsburgh; S. Gips, Morristown Me-
morial Hospital; W. Hathaway, LaSalle Clinic, Appleton;
S. E. Hearne, Peninsula Regional Medical Center, Salis-
bury; W. Herzog, University of Maryland Hospital,
Baltimore; K. Hicks, Madigan Army Medical Center,
Tacoma; M. Holland, Boulder Medical Center; E. Hope,
Cardiology Associaties of West Reading; A. C. Jain, West
Virginia University, Morgantown; L. Karagounis, VA Hos-
pital, Salt Lake City; R. Kerensky and J. D. Schlaifer,
University of Florida, Gainesville; P. Koren, Cooper Uni-
versity, Camden; M. Kozak, Hershey Medical Center; K.
Kruse, Carrabus Memorial Hospital, Concord; G. S. Led-
ley, Albert Einstein Medical Center, Philadelphia; J. T.
Mann, Wake Medical Center, Raleigh; J. Martin, Bryn
Mawr Hospital; M. J. Martinelli, Albany Medical Associ-
ates; M. J. Miller, East Carolina University, Greenville; B.
Muhlestein, Latter Day Saints Hospital, Salt Lake City; D.
Nardone, Williamsport Hospital; J. S. Reiner, George
Washington University Hospital, Washington; J. Resar,
Johns Hopkins Hospital, Baltimore; K. Rocha-Singh,
South Illinois University School of Medicine, Springfield;
R. Rubinstein, Jersey Shore Medical Center, Neptune; R.
Safian, William Beaumont Hospital, Royal Oak; E. San-
toian, Orlando Regional Medical Center; K. Sheikh,
Woesthoff Memorial Hospital, Merritt Island; R. F. Sisson,
Forsyth Memorial Hospital, Winston-Salem; J. O. Smith,
University Community Hospital, Tampa; T. Spaedy, Boone
Hospital, Columbia; D. Spriggs, Morton Plant Hospital,
Clearwater; J. D. Talley, University of Arkansas, Little
Rock; H. Tamboli, Tampa General Hospital; M. Taniuchi,
Washington University School of Medicine, St. Louis; P.
Teirstein, Scripps Clinic and Research Foundation, La
Jolla; M. Thompson, Rochester General Hospital; M. B.
Weiss, Westchester County Medical Center, Valhalla;
D. O. Williams, Rhode Island Hospital, Providence;
J. S. Wilson, Allegheny General Hospital, Pittsburgh;
J. P. Zidar, Duke University Medical Center, Durham; A.
Bartel, Sentara Norfolk General Hospital; F. Navetta,
Trinity Mother Frances Hospital, Tyler.
Clinical Events Committee: K. W. Mahaffey (Chair-
man), L. Goetz-Brown, R. Lail, D. Brown, M. Cuffe, K.
Alexander, D. Whellan, D. Kong, M. Madden, J. Alex-
ander.
Angiographic Core Laboratory: A. M. Ross, C. Lunder-
gan.
1613i Batchelor et al. JACC VOl. 38, No. 6, 2001
Enoxaparin in High-Risk Stenting November 15, 2001:1608–13i
